Evaluation of physical activity in sarcopenic conditions of kidney transplantation recipients.

INTRODUCTION: Sarcopenia is an involuntary decline in skeletal muscle mass, strength, and function that normally proceed with aging but may develop faster under some chronic disease conditions. In this study, we compared the physical activity between sarcopenia and non-sarcopenia subgroups in kidney transplant recipients. METHODS: Fifty-eight recipients (42 males and 16 females) were enrolled in this study. Mean age of the recipients was 46.6 ± 12.7 years. Mean duration of dialysis was 2.8 ± 4.0 years. Diagnostic criteria for sarcopenia referred to those of the Asia Working Group for Sarcopenia. The physical activity was assessed using the International Physical Activity Questionnaire, and the intensity of physical activity was expressed in metabolic equivalents (MET). RESULTS: Based on the skeletal muscle mass index (SMI) as well as functional index (HGS, walking speed), the participants were classified into the three subgroups: 12 patients (20.7%) with sarcopenia (Group 1), 25 (43.1%) with presarcopenia (Group 2), and 21 (36.2%) non-sarcopenia (Group 3). Analysis with ANOVA and pairwise comparisons showed that physical activity measured as total MET-min/week was significantly greater in Group 2 (1292 ± 633) than in Group (1484 ± 262). Moreover, physical activity of Group 3 (2461 ± 1339)-min/week was significantly greater than those of Groups 1 and 2. CONCLUSIONS: Our data indicate that physical activity is restricted under presarcopenia and sarcopenia after kidney transplantation. Considering that the recipient age is now increasing, proper management of sarcopenia may become more crucial to improve the kidney survival and lifetime prognosis of the kidney transplant recipients.

Renal and vascular protective effects of ezetimibe in chronic kidney disease.

OBJECTIVE: Dyslipidemia is a risk factor for not only cardiovascular diseases (CVD), but also chronic kidney disease (CKD). Ezetimibe, a cholesterol absorption inhibitor, lowers cholesterol levels by inhibiting both extrinsic and intrinsic cholesterol absorption via the gastrointestinal duct. However, very few studies have examined its efficacy and safety for patients with dyslipidemia complicated with CKD. METHODS: Thirty-seven dyslipidemic patients (low density lipoprotein cholesterol (LDL-C) levels ≥120 mg/dL) complicated with CKD were given ezetimibe (10 mg/day) for twenty-four weeks. The efficacy and safety of the therapy, including the anti-atherosclerotic and renal protective effects, were then examined. RESULTS: Significant decreases were observed in the levels of LDL-C (158.9 ± 26.9 mg/dL→123.0 ± 31.8 mg/dL; p<0.0001), remnant-like lipoprotein cholesterol (9.3 ± 5.3 mg/dL→7.3 ± 3.8 mg/dL; p<0.05) and lipoprotein (a) (22.0 ± 16.1 mg/dL→16.4 ± 11.0 mg/dL; p<0.01). The estimated glomerular filtration rate did not change, but the urine protein to creatinine ratio decreased significantly (1,107.3 ± 1,454.2 mg/gCre→732.1 ± 1,237.8 mg/gCre; p<0.05). No changes were observed in the carotid intima media thickness, but the brachial-ankle pulse wave velocity decreased significantly (1,770.4 ± 590.3 cm/sec→1,702.5 ± 519.9 cm/sec; p<0.05). No adverse events were observed. CONCLUSION: Ezetimibe can be safely administered even to patients with CKD. The results of this study indicate that ezetimibe may provide some renal protection and suppress the complications of CVD in CKD patients.

Decreased plasma level of vitamin C in chronic kidney disease: comparison between diabetic and non-diabetic patients.

BACKGROUND: A decreased plasma level of vitamin C has been reported to be associated with an increased risk of cardiovascular morbidity and mortality. Here, we sought to determine the vitamin C status of patients with chronic kidney disease and the pathophysiological role of vitamin C in these patients. METHODS: We studied 58 patients and evaluated the relationship between renal function and plasma vitamin C concentration, as well as the effect of diabetes on this relationship. Endothelium-dependent flow-mediated dilation of brachial artery was measured to assess the endothelial function. Serum malondialdehyde low-density lipoprotein was measured as a marker for oxidative stress. RESULTS: Plasma vitamin C concentration had a positive linear relationship with eGFR in both diabetic and non-diabetic patients (P = 0.006 and P = 0.004, respectively). When vitamin C concentration and eGFR relationships were compared in the two groups, vitamin C concentration was significantly lower in diabetic patients at every eGFR (P = 0.006). Flow-mediated vasodilatation of the brachial artery was positively correlated with vitamin C concentration in non-diabetic patients (P = 0.047) but not in diabetic patients. There was a negative correlation between serum malondialdehyde low-density lipoprotein and vitamin C concentration in non-diabetic patients (P = 0.044) but not in diabetic patients. CONCLUSIONS: Renal dysfunction was associated with a decrease in plasma vitamin C level. Moreover, decreased vitamin C may cause endothelial dysfunction via an increase in oxidative stress in non-diabetic chronic kidney disease patients.